Advertisement

Picture Kentro Design Corporate and Web Design Berlin 650x65px
Person › Details

Christian Seegers (IBB Beteiligungsgesellschaft mbH)

Seegers, Christian (Berlin (govt) 201111 Senior Investment Manager Life Science at IBB Beteiligungsges)

 

Organisation Organisation IBB Beteiligungsgesellschaft mbH
  Group Berlin (govt region)
Products Product venture capital
  Product 2 LIFE SCIENCES
     

Myelo Therapeutics GmbH. (9/23/13). "Press Release: Myelo Therapeutics GmbH Closes Financing Round for Development of Adjuvant Cancer Therapy". Berlin.

Myelo Therapeutics GmbH announced today the successful closing of its series A financing for developing an innovative adjuvant cancer therapy. The round was co-led by the venture capital investors IBB Beteiligungsgesellschaft mbH with its VC Fonds Technologie Berlin and Eckert Wagniskapital und Frühphasenfinanzierung GmbH and the pharmaceutical company JSC Valenta Pharmaceuticals.

The capital raised enables Myelo Therapeutics GmbH to develop its lead compound, Myelo001, a small molecule for the treatment of patients with chemotherapy-induced neutropenia and thrombocytopenia, a multi-billion dollar market, through preclinical and early clinical development.

Till Erdmann, co-founder and Managing Director responsible for business development and investor relations, declared, "We have been able to secure the support of a range of outstanding institutional and strategic investors with a well-defined development strategy for an innovative compound in an area with a high unmet medical need."

Dirk Pleimes, co-founder, Managing Director and Chief Medical Officer, added, "Myelo001 offers a new approach applied per os in the treatment of chemotherapy-induced neutropenia and thrombocytopenia. New adjunct treatment options are needed for cancer patients undergoing chemotherapy to support optimal treatment and improve outcomes. Myelo Therapeutics has already started the preclinical program for Myelo001 and is committed to addressing unmet needs of cancer patients by developing this innovative medicine."

"This compound has shown its potential in several indications. I am satisfied that we are now starting development in chemotherapy-induced neutropenia as a first step," says Dr. Vladimir Nebolsin, inventor of Myelo001.

Alexander Itin, CEO of JSC Valenta Pharmaceuticals, comments: "We welcome the opportunity to participate in this venture. Myelo001 has already demonstrated significant benefits for patients in some of our core markets. We are now eager to see its development for pharmaceutical markets in Europe and the US."

"Myelo Therapeutics' founders convinced us with their solid industry and medical experience, as well as with an innovative compound that has high market potential," said Christian Seegers, senior investment manager of the IBB Beteiligungsgesellschaft. "We are convinced that financing Myelo Therapeutics GmbH further promotes the strong pharmaceutical environment in Berlin."


About Myelo Therapeutics GmbH

Myelo Therapeutics is a pharmaceutical company based at the Biotech Park Berlin-Buch, Germany that is developing innovative treatments in areas of high unmet medical needs. For more information, visit www.myelotherapeutics.com.

Contact:

Myelo Therapeutics GmbH
Till Erdmann,
Managing Director
Robert-Rössle-Strasse 10
Building B 55
13125 Berlin
Germany
Phone: +49 (0) 170 9126 402
E-mail: info@myelotherapeutics.com
www.myelotherapeutics.com


About IBB Beteiligungsgesellschaft mbH

The IBB Beteiligungsgesellschaft (www.ibb-bet.de) provides venture capital to innovative Berlin enterprises and has established itself as a market leader in the field of early stage financing in Berlin. The funds are used primarily for the development and market launch of innovative products or services, as well as for business concepts of creative industries. Currently two of the funds managed by the IBB Beteiligungsgesellschaft are in the investment phase, the VC Fonds Technologie Berlin with a fund size of €52 million and the VC Fonds Berlin Kreativwirtschaft Berlin with a fund size of €30 million. Both VC funds are financed by means of the Investitionsbank Berlin (IBB) and the European Fund for Regional Development (EFRE) administered by the State Berlin. Since 1997 the IBB Beteiligungsgesellschaft Berlin, in consortia with partners, has made €850 million available to creative and technology-oriented companies; of this, the portion invested by IBB Beteiligungsgesellschaft itself, as lead, co-lead or co-investor, was approximately €116 million.

Contact:

IBB Beteiligungsgesellschaft mbH
Christian Seegers
Bundesallee 210
10719 Berlin
Germany
Phone: +49 (0) 30 2125 3201
Fax: +49 (0) 30 2125 3202
Email: venture@ibb-bet.de
www.ibb-bet.de


About Eckert Wagniskapital und Frühphasenfinanzierung GmbH

Eckert Wagniskapital und Frühphasenfinanzierung GmbH is a venture and early-phase financer that has specialised for over 20 years in technology-oriented manufacturing companies in the field of life sciences (biotechnology, medical technology, pharmacy), broadly interpreting life science to include related topics and industries such as analytics, material science and clinical developments. The regional focus is on Berlin and its environs, and, in terms of life cycle, investments are mainly made into start-ups or early phases. Among the most successful EWK company foundings are Eckert & Ziegler AG (www.ezag.de) and Glycotope (www.glycotope.com). In total since 1990, the EWK portfolio has supported nearly 20 companies and start-ups.

Contact:

Eckert Wagniskapital und Frühphasenfinanzierung GmbH
Robert-Rössle-Str. 10
13125 Berlin
Germany


About JSC Valenta Pharmaceuticals

JSC Valenta Pharmaceuticals is one of the largest Russian pharmaceutical companies. Its products are sold in 18 countries. The company develops, manufactures and sells both prescription and OTC (over the counter) medications. It owns a broadly diversified portfolio of originator drugs, including Ingavirin (antiviral medicine), Zydena (erectile dysfunction), Phenotropil (nootropic, neuromodulator), Grammidin (infectious throat diseases), Zorex (abstinence syndrome treatment). The company has also successfully developed branded generics drugs, such as Zitrolid (antibacterial), Cardiodaron (antiarrhythmic), Pantocalcin (nootropic), and Teraligen. Revenues for 2012 amounted to €129 million (5,189,453 thousand rubles), with investment in research and development of €5.8 million (236,164 thousand rubles / in accordance with IFRS). For more information, visit http://www.valentapharm.com/eng.

Contact

JSC Valenta Pharmaceuticals
General Manager
Alexander Itin
Generala Dorokhova str., 18-2
Moscow, Russia
Phone: +7 495 933 60 80

   
Record changed: 2019-08-28

Advertisement

Picture [LSE] Life-Sciences-Europe.com – The Business Web Portal 650x65px


More documents for Christian Seegers


To subscribe to our free, monthly newsletter for the European life sciences, please send an e-mail to info@iito.de and simply fill the subject line with the word »LSE Newsletter«

To get even more information, please take a look at our [gs] professional services offering and read the gene-sensor Product Flyer [PDF file]

Please visit also our web portals for the European life sciences and the worldwide mass spectrometry industry at Life-Sciences-Europe.com (European life sciences) and Mass-Spec-Capital.com (worldwide mass spectrometry)

Please visit also our web portals for the life sciences in German-speaking Europe (DE, AT & CH) and the worldwide mass spectrometry industry at Life-Sciences-Germany.com (life sciences in German-speaking Europe) and Mass-Spec-Capital.com (worldwide mass spectrometry)

Advertisement

Picture ConsulTech GmbH Berlin Grant Application and Coordination 650x80px




» top